Loading organizations...
§ Venture Capital · Lanham, MD, USA
A firm whose name suggests venture capital or investment activities, potentially connected to the San Francisco area.
415 Capital is a venture capital firm focused on MedTech innovation. It invests in breakthrough medical technologies addressing unmet patient needs in chronic diseases, particularly cardio and neurovascular disorders. The firm provides portfolio companies with capital, expertise, and market access, accelerating development and commercialization.
The firm's foundation stems from a team history spanning three decades, contributing to advancements in cardiovascular and neurovascular care. Established in 2018, General Partners Frederik Groenewegen and David Thompson leverage this pedigree. Their founding insight applies deep domain knowledge and networks to identify and support medical innovations.
415 Capital’s investment and strategic support target entrepreneurs and early-stage MedTech companies developing solutions for widespread chronic illnesses. These efforts enhance patient outcomes and improve quality of life. The firm’s vision is to drive down long-term healthcare costs by pioneering medical technologies addressing critical global health challenges.
415 Ventures has 1 tracked investment across 1 company. The latest tracked deal is $2.0M Seed in Prellis Biologics in September 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2017 | Prellis Biologics | $2.0M Seed | True Ventures | Cultivation Capital, Momenta Ventures, SUE XU, Civilization Ventures |